<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100713004364N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-09-11</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of Turmeric tablet on serum and follicular fluid  inflammatory and oxidative stress indicators in women with polycystic ovary syndrome undergoing infertility treatment</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of Turmeric tablet on serum and follicular fluid  inflammatory and oxidative stress indicators in women with polycystic ovary syndrome undergoing infertility treatment</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-06-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71768</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Basic scienece, Randomization description: A study is a three-blind randomized controlled trial in which the sampling will be continuous and the allocation of samples to the study groups will be random. Allocation of samples into two intervention and placebo groups will be done randomly and through the quadruple block method. The method of block classification is determined by someone other than the researcher using the seal envelope site, and the blocks are placed in opaque numbered envelopes, Blinding description: It is a three-blind randomization (researcher, people participating in the research, and a statistician).</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Polycystic ovary syndrome. Condition 2: Women Infertility.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Turmeric tablet containing 450 mg of turmeric rhizome powder and 50 mg of turmeric extract, which is standardized by Dineh Pharmaceutical Company with drug registration number 7796008783541035, based on 5.47 mg of curcumin. 3 tablets are given daily to the internal group for 6 weeks. Intervention 2: Control group: Placebo tablets containing 500 mg of maltodextrin are used 3 times a day by Dineh Pharmaceutical Company for 6 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is there is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Leila Amini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rashid Yasmi St. above Vanak Square, Vali Asr St. (AJ)</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>88201978</zip>
        <telephone>+98 21 8888 2886</telephone>
        <email>amini.l@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Leila Amini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Rashid Yasmi St. above Vanak Square, Vali Asr St</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>88201978</zip>
        <telephone>+98 21 8888 2886</telephone>
        <email>mahboubehkarimi78@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women undergoing IVF infertility treatment
Iranian origin
Ages 18-40 years
married
Body mass branch below 30 kg/m2</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>1) Consumption of food and pharmaceutical supplements
2) Adhering to a special diet such as vegetarianism
3) Women with a history of infertility with simultaneous diagnosis of polycystic ovary syndrome and endometriosis
4) Hepatic and biliary disorders
5) under treatment with anticoagulant drugs
6) Active gastric ulcer
7) Having a history of allergy to turmeric or its products
8) Slimming diets
9) Athletes or special sports</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E28.2</hc_code>
      <hc_code>N97</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Polycystic ovarian syndrome</hc_keyword>
      <hc_keyword>Female infertility</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Turmeric tablet containing 450 mg of turmeric rhizome powder and 50 mg of turmeric extract, which is standardized by Dineh Pharmaceutical Company with drug registration number 7796008783541035, based on 5.47 mg of curcumin. 3 tablets are given daily to the internal group for 6 weeks.</i_keyword>
      <i_keyword>Control group: Placebo tablets containing 500 mg of maltodextrin are used 3 times a day by Dineh Pharmaceutical Company for 6 weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>"Changes in inflammatory indices in women with polycystic ovary syndrome". Timepoint: 6 weeks after starting to take turmeric tablets. Method of measurement: Inflammatory indices in this study mean the measurement of C-reactive protein (in milligrams per liter), interleukin-6 (ELISA method) and the ratio of neutrophils to lymphocytes in the serum and follicular fluid of patients.                                 IL-6: Interleukin 6 Human Platinum ELISA kit with ELISA method; It can be measured with a sensitivity of 0.92 pg/m and with a normal range of results: 1-100 pg/ml.                                           CRP: Bionik CRP biochemistry kit made in Iran with photometric method and normal range of results: values up to 6 mg/L can be measured.                                             Neutrophil to lymphocyte ratio: Sysmex model N-21KX machine is used for cell counting and to determine the percentage of neutrophils and lymphocytes, visual method or light microscope and Giemsa staining are used.</prim_outcome>
      <prim_outcome>And "Changes in oxidative stress indices in women with polycystic ovary syndrome". Timepoint: 6 weeks after starting to take turmeric tablets. Method of measurement: Oxidative stress indicators: Oxidative stress indicators in this research mean the measurement of malondialdehyde MDA (in micromolar per liter), total antioxidant capacity TAC and reactive oxygen radical ROS (milliunits per milliliter) in serum and follicular fluid of patients .     MDA: It is measured using a 96-piece Well-plate kit made in Iran, Kia Biot Company, with a fluorimetric method that has a normal dynamic range: 20-100 µm.                               TAC: It is measured using a 96-piece Clean photometric plate well kit made in Iran, Kia Zeet company, with the Kuprak method, which has a dynamic range of 40-400 nmol/ml.                                                                                                    ROS: It is measured by flow cytometry and fluorimetry using a kit of 96 Well Sterile Fluorimetric plates made in Iran, Kia Life Company. The fluorophore can be read at a wavelength of 525-485 Em/Ex=nm in plate fluorimetry or flow cytometry.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Dineh Pharmaceutical Company of Iran</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
      <source_name>Dineh Pharmaceutical Company of Iran</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-07-31</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciece</contact_name>
        <contact_address>Nursing &amp; Midwifery faculty, Yasemi Ave, Valiasr St Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
